151 related articles for article (PubMed ID: 37798914)
1. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
[TBL] [Abstract][Full Text] [Related]
2. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
[TBL] [Abstract][Full Text] [Related]
3. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
[TBL] [Abstract][Full Text] [Related]
5. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
6. A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
Nakamura K; Fujimoto K; Hasegawa C; Aoki I; Yoshitsugu H; Ugai H; Yatsuzuka N; Tanaka Y; Furihata K; Maas BM; Wickremasingha PK; Duncan KE; Iwamoto M; Stoch SA; Uemura N
Clin Transl Sci; 2022 Nov; 15(11):2697-2708. PubMed ID: 36053806
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
8. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33649113
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
Lee CC; Hsieh CC; Ko WC
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
[TBL] [Abstract][Full Text] [Related]
10. Molnupiravir: an antiviral drug against COVID-19.
Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
[TBL] [Abstract][Full Text] [Related]
11. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
12. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Johnson MG; Strizki JM; Jensen E; Cohen J; Katlama C; Fishchuk R; Ponce-de-León A; Fourie N; Cheng C-Y; McCoy D; Vesnesky M; Norice CT; Zhang Y; Williams-Diaz A; Brown ML; Carmelitano P; Grobler JA; Paschke A; De Anda C
Microbiol Spectr; 2024 Mar; 12(3):e0356323. PubMed ID: 38299867
[TBL] [Abstract][Full Text] [Related]
13. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
[TBL] [Abstract][Full Text] [Related]
14. Molnupiravir for the treatment of COVID-19.
Santani BG; LeBlanc BW; Thakare RP
Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
[TBL] [Abstract][Full Text] [Related]
15. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
[TBL] [Abstract][Full Text] [Related]
16. Molnupiravir: Mechanism of action, clinical, and translational science.
Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA
Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352
[TBL] [Abstract][Full Text] [Related]
17. Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
Iwamoto M; Duncan KE; Wickremasingha PK; Zhao T; Liberti MV; Lemoine L; Decaesteker T; Rottey S; Maas BM; Gillespie G; Stoch SA
Clin Transl Sci; 2023 Oct; 16(10):1947-1956. PubMed ID: 37526305
[TBL] [Abstract][Full Text] [Related]
18. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
[TBL] [Abstract][Full Text] [Related]
19. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
[TBL] [Abstract][Full Text] [Related]
20. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.
Chang CH; Peng WY; Lee WH; Yang L; Lin TY; Yang MH; Tsai TH
Commun Med (Lond); 2023 Oct; 3(1):150. PubMed ID: 37857815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
